. Author manuscript; available in PMC: 2017 Dec 1.

Published in final edited form as: Support Care Cancer. 2016 Jul 27;24(12):4839–4847. doi: 10.1007/s00520-016-3338-4

Table 2.

Unadjusted and Adjusted Associations of Race with Post-Chemotherapy Utilization

	Risk and 95% Confidence Intervals				Risk Ratios and 95% Confidence Intervals, Black v. White
	Unadjusted models		Models adjusted for clinical characteristics		Unadjusted models	Models adjusted for clinical characteristics
	White	Black	White	Black
CINV-Related Utilization
Any	0.23 (0.21–0.26)	0.15 (0.10–0.23)	0.24 (0.14–0.42)	0.16 (0.08–0.32)	0.63^a (0.40–0.99)	0.66 (0.42–1.04)
Outpatient visits	0.23 (0.21–0.26)	0.15 (0.09–0.23)	0.23 (0.13–0.41)	0.15 (0.08–0.311)	0.64^a (0.41–1.01)	0.67 (0.43–1.06)
ED visits & inpatient admissions^b	0.03 (0.02–0.05)	0.03 (0.01–0.09)	--	--	1.07 (0.39–2.97)	--
Any Post-Chemotherapy Utilization	0.91 (0.89–0.93)	0.87 (0.81–0.93)	0.88 (0.80–0.96)	0.84 (0.74–0.94)	0.95 (0.89–1.03)	0.95 (0.89–1.03)
Utilization For Other Side Effects
Fatigue	0.06 (0.05–0.08)	0.03 (0.01–0.08)	0.02 (0.00–0.09)	0.01 (0.00–0.07)	0.43 (0.14–1.36)	0.45 (0.14–1.44)
Neutropenia	0.41 (0.38–0.44)	0.37 (0.30–0.47)	0.35 (0.24–0.52)	0.32 (0.21–0.50)	0.92 (0.72–1.18)	0.90 (0.71–1.16)

Estimates in bold are marginally statistically significant (p=0.05)

Only unadjusted models for ED visits and inpatients admissions were run due to very low frequency of this outcome, resulting in insufficient cell sizes